Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 3Phase 1 3Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 10Pancreatic Neoplasms 3Colorectal Neoplasms 2Rectal Neoplasms 1Phase I: To Determine the Maximum Tolerated Dose (MTD) 1Neuroendocrine Tumors 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 13Cisplatin 10pembrolizumab 7Oxaliplatin 5Leucovorin 5Fluorouracil 5durvalumab 4Paclitaxel 4Nivolumab 3Injections 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Docetaxel 2Cetuximab 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1surufatinib 1spartalizumab 1silmitasertib 1regorafenib 1pertuzumab 1manganese chloride 1lenvatinib 1irinotecan sucrosofate 1folfirinox 1devimistat 1derazantinib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Biliary Tract Neoplasms × S 1 (combination) × Clear all
NCT01284413 2014-07-01

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Kansai Hepatobiliary Oncology Group

Phase 1/2 Completed
68 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡